On Covid, Govtâs twin concerns: spreading reach, rising case count
đ´ Elaborating on the âtwin concernsâ, the Ministry flagged eight states with rising positivity rates and a significant increase in caseload: Maharashtra, West Bengal, Delhi, Tamil Nadu, Karnataka, Uttar Pradesh, Kerala, and Gujarat.
And while Dr V K Paul, who heads the national Covid task force, described the positivity rates as âphenomenally highâ, the Union Health Ministry flagged a spike in the total number of active cases reported from several pockets in states across the country. (File)
Advertisement
THE CENTRE Wednesday said that while hospitalisation at current levels may be low amid the Omicron surge, Covid cases are spreading at a large scale, with a progressive increase in the number of districts reporting a rise in positivity â in just one week, ending January 11, 300 districts reported more than 5 per cent positivity rate compared to just 78 in the previous week.
And while Dr V K Paul, who heads the national Covid task force, described the positivity rates as âphenomenally highâ, the Union Health Ministry flagged a spike in the total number of active cases reported from several pockets in states across the country.
You have exhausted your monthly limit of free stories.
Read more stories for free with an Express account.
Elaborating on the âtwin concernsâ, the Ministry flagged eight states with rising positivity rates and a significant increase in caseload: Maharashtra, West Bengal, Delhi, Tamil Nadu, Karnataka, Uttar Pradesh, Kerala, and Gujarat (see box).
The Ministry also pointed to six other states that have reported more than a six-fold rise in cases from the previous week. Bihar tops this list with a 11-fold rise in cases followed by Madhya
Pradesh, Rajasthan, Odisha, Punjab and Chhattisgarh.
âThe intensity of the pandemic has increased. It is quite clear from the data that it is being driven and powered by Omicron. It is rapidly replacing or has replaced the previous dominant Delta variant. Omicron has high transmissibility and growth rateâŚwe are seeing phenomenally high test positivity rates,â Paul, who is also a NITI Aayog member, said.
He reiterated that Omicron is ânot a common coldâ and said that the latest variant has the potential to overwhelm health infrastructure.
âUnderstanding the disease from an Indian experienceâŚit looks that the hospitalisation rate may be low. Maybe. But it is spreading at a large scale. One is infected, the entire family gets infected. We cannot lower vigil and preparedness. I endorse the statement of WHO: Omicron is not a common cold. It is not a simple or ordinary infection. We cannot take this lightly,â Paul said.
Story continues below this ad
âAlso, the current situation is like this because of high vaccination rates⌠because vaccines provide protection against severe disease. So Omicron is not a common cold and because of it, many health systems have collapsed in a few countries. Many health workers have been forced to stay at home. There is more pressure. We have to slow the transmission,â he said.
The Centre, meanwhile, cautioned against ârampant and irrational useâ of Molnupiravir, the first antiviral drug granted emergency use authorisation by the national regulator, and emphasised that efforts should be made to restrict its use as âknown and unknown harms far outweigh its claimed benefitâ.
ICMR chief Dr Balram Bhargava cited experts in the Covid task force to warn that certain risks warrant caution in the use of Molnupiravir.
âWe had extensive debate and discussion among national expertsâŚ.The final conclusion was that Molnupiravir has certain risks that warrant caution in its use. Number two, experts present at the meeting opined that there is a rampant and irrational use of Molnupiravir. Number three, efforts should be made to restrict its use as known and unknown harms far outweigh its claimed benefit,â Bhargava said.
Story continues below this ad
âNumber four, the currently available synthesised evidence was reviewed, and the members unanimously agreed that it does not merit the inclusion of Molnupiravir in national treatment guidelines. The emerging evidence will be constantly reviewed,â he said.
sâLastly, it was further highlighted that the current clinical window of an application appears extremely narrow for Molnupiravir with relevance only to the following: elderly, unvaccinated with other comorbidities. There is no evidence of benefit in diabetes, and those who were previously infected with Covid-19 or were vaccinated,â he said.
Paul, too, expressed âconcernâ over the irrational consumption of drugs for Covid treatment.
âWhichever medicines are being given, there should be a rational approach in using them. There cannot be overuse. In the last wave, we witnessed a scary situation, where the overuse of drugs caused mucormycosis (black fungus)âŚThere is a guilt that there was an overuse. Steroids are very potent and life-saving drugs, but they also have side effects. They disturb many biochemical pathways. We have learned our lessons. We donât want that situation to repeat,â he said.
Story continues below this ad
âFor mild symptoms, in case of fever, only paracetamol should be given. For cough, one can take cough syrup, warm water, and gargleâŚif cough persists for more than five days, in selected cases, you can use inhalation budesonide (a repurposed medication to prevent asthma symptoms). These are the only three things to be done,â Paul said.
Kaunain Sheriff M is an award-winning investigative journalist and the National Health Editor at The Indian Express. He is the author of Johnson & Johnson Files: The Indian Secrets of a Global Giant, an investigation into one of the worldâs most powerful pharmaceutical companies.
With over a decade of experience, Kaunain brings deep expertise in three areas of investigative journalism: law, health, and data. He currently leads The Indian Express newsroomâs in-depth coverage of health.
His work has earned some of the most prestigious honours in journalism, including the Ramnath Goenka Award for Excellence in Journalism, the Society of Publishers in Asia (SOPA) Award, and the Mumbai Press Clubâs Red Ink Award.
Kaunain has also collaborated on major global investigations. He was part of the Implant Files project with the International Consortium of Investigative Journalists (ICIJ), which exposed malpractices in the medical device industry across the world. He also contributed to an international investigation that uncovered how a Chinese big-data firm was monitoring thousands of prominent Indian individuals and institutions in real time.
Over the years, he has reported on several high-profile criminal trials, including the Hashimpura massacre, the 2G spectrum scam, and the coal block allocation case. Within The Indian Express, he has been honoured three times with the Indian Express Excellence Award for his investigationsâon the anti-Sikh riots, the Vyapam exam scam, and the abuse of the National Security Act in Uttar Pradesh. ... Read More